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A clinical evaluation of the new dialysers. Seventeen hemodia-
lysers, studied by one team using the same techniques through-
out, are compared in terms of their clearance of urea and crea-
tinine, priming volume, residual blood volume, ultrafiltration
rate, handling and cost. Data on clearance of higher molecular
weight substances are also presented for six of the dialysers.
The Meltec I m Multipoint dialyser has a considerable superio-
rity over the Kiil of the same surface area in clearance of all
molecules studied, a higher ultrafiltration rate and similar prim-
ing volume, residual blood volume, handling characteristics and
cost. Of the disposable dialysers the EX-03, Nephravon, Ultraflo
100 and Ultraflo 2 coils and the Dasco SP 400, Gambro Lundia
and Rhone Poulenc ID parallel flow dialysers all have urea and
creatinine clearances superior to the Kiil. There are small differen-
ces in performance between members of this group but they are
counterbalanced by differences in priming volume, flexibility of
ultrafiltration, ease of handling, leakage rate and cost. Thus
there is no single disposable dialyser which has a clearcut superio-
rity over its rivals. The Cordis HFAK has a considerably higher
urea and creatinine clearance than any other disposable dialyser
but its clearance of large molecules is lower and its residual blood
volume higher when compared to the Kiil.
Evaluation clinique des nouveaux dialyseurs. Dix-sept hémo-
dialyseurs, étudiés par une équipe qui emploie constamment les
mémes techniques, sont compares en ce qui concerne: leurs
clearances de l'urée et de la créatinine, le volume initial né-
cessaire, le volume de sang résiduel, le debit d'ultrafiltration, le
maniement et le coüt. Des résultats en cc qui concerne Ia clearance
des substances de poids moléculaires plus élevés sont présentés
pour six de ces dialyseurs. Le dialyseur Meltec 1 m2 a une su-
périorité considerable sur Ic Kiil de méme surface pour Ia
clearance de toutes les molecules étudiées, un debit d'ultrafil-
tration supérieur et ii est semblable en ce qui concerne le volume
initial nécessaire, le volume de sang résiduel, Ic maniement et Ic
coüt. Parmi les dialyseurs jetables les EX-03, Nephravon, Ultra-
flo 100 et Ultraflo a 2 bobines et Dasco SP 440, Gambro Lundia
et Rhone Poulenc 1 D ont tous des clearances de l'urée et de Ia
créatinine supérieures au Kiil. Ii y a des petites differences parmi
les éléments de ce groupe mais elles sont compensées par des
differences de volume initial nécessaire, de flexibilité de l'ultrafil-
tration, de facilité de maniement, de fréquence de fuite et de
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coüt de telle sorte qu'aucun dialyseur jetable n'a une supériorité
évidente sur ses concurrents. Le Cordis HFAK a des clearances
de l'uré et de Ia créatinine considérablement supérieures a celles
de n'importe quel autre dialyseur jetable mais sa clearance des
grosses molecules est inférieure et son volume de sang résiduel
supérieur a ceux du Kiil.
In 1969 Dittrich and his colleagues [1] described 67
hemodialysers which had reached the stage of construction,
clinical trial and publication. However, most of these were
already museum pieces and by 1969 two designs, the Kiil
and Travenol Twin Coils, accounted for four-fifths of all
European dialyses [21. in the last three years the choice has
widened again to the point of bewilderment. Descriptions
of most of the new dialysers have been published but me-
thods of evaluation vary from center to center and the
publications often omit some of the vital information which
is essential for rational judgement of a dialyser [3, 4]. Dia-
lyser design is a compromise between conflicting demands;
manufacturers' literature naturally stresses the good points
with little mention of the defects which had to be accepted
in this compromise.
To provide a better basis for choice of equipment the
Department of Health and Social Security supports a dia-
lyser testing program at Newcastle upon Tyne. In the
last two years we have evaluated on their behalf most of the
artificial kidneys in widespread use in Europe and several
which have just been launched on the market. We present
data on 17 dialysers compared in vitro and in vivo by the
same team using the same techniques throughout.
Methods
The full evaluation of a dialyser [4] involves the measure-
ment of several parameters of greater interest to the engi-
neer than the clinician. We took a selection of the most im-
portant characteristics which we regarded as the minimum
basis for clinical comparison (Table 1). We have virtually
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Table 1. Minimum information required for choice between
dialysers
Criterion Conditions of study
Conditions chosen
for this
investigation
Clearance Of urea and creatinine
at clinically useful blood
flow rates and standard
dialysis fluid addition
rate or flow rate
Blood flow,
75-300 mi/mm
Dialysis fluid flow
rate, 500 mI/mm
Blood com- At standard trans- Transmembrane
partment membrane pressure pressure,
volume approximating
clinical conditions
100 mm Hg
Dynamic blood Over the range likely Increment with in-
compartment to be employed in crease in transmem-
volume ultrafiltration brane pressure of
100mm Hg
Residual After standard Saline wash-in of
blood volume method of returning
blood to patient
800 ml
Ultrafiltration At standard transmem- Transmembrane
rate brane pressure pressure of 100 and
200mm FIg
Convenience Ease of assembly
(if required)
Ease of handling
Pyrogenicity
Leakage rate
Assembly
Handling
Cost Direct cost of diylser
Indirect costs
(labour, etc.)
Direct cost
confined our attention to dialysis with the aid of blood
pumps since the majority of our patients now use arterio-
venous fistulae.
Clearance studies were carried out in viva on patients
undergoing thrice weekly hemodialysis for chronic renal
failure during the second to fourth hour of dialysis, when
conditions are stable; a considerable fall-off in performance
may occur in the first hour [5, 6]. Dialysis fluid flow rate
was set at 500 mI/mm on the flow meter of a Lucas single-
patient proportioning system and checked by timed collec-
tion of two one-minute samples. One ml samples of he-
parinized blood were placed in Autoanalyser cups and
allowed to sediment while protected from evaporation.
Urea and creatinine concentrations were measured in the
layer of plasma using a two-channel Autoanalyser. Dialysis
fluid dextrose concentration was 200 mg/l00 ml resulting in
arterial and venous plasma dextrose concentrations in the
range of 70 to 110 mg/lOO ml during the test period. These
concentrations of dextrose cause an overestimate of plasma
creatinine which does not exceed 0.1 mg/lOOml in our
modification of the standard Technicon creatinine method
and this small error has been ignored. Blood flow rate was
measured by bubble transit time over a two meter track
using the mean of three measurements.
When one type of disposable dialyser was evaluated
clearance studies were measured at six or seven different
blood flow rates on eight to 12 separate dialysers, studies
continuing until it was obvious that a fitted curve would
have an acceptably low standard error. These numbers are
in line with the subsequent recommendations of the Gotch
committee [41.
The number of separate non-disposable dialysers from
which clearance data were obtained were 12, 10, 7, 2 and 3
for the Watson Marlow Kiil, Kiil plus Bier-Staynes insert,
Meltec Multipoint 1 m2, 0.77 m2 and 0.61 m2, respectively.
When we had only a few dialysers available for test (Meltec
0.77 and 0.61 m2) these were reassembled on several oc-
casions. The resulting 50 to 80 clearance measurements were
fed into an IBM computer programmed to give a mean
curve using the formula:
blood flow rate
clearance = A+B x blood flow rate
(where A and B are constants) with 95% confidence limits of
the mean by least squares approximation.
Clearances of higher molecular weight substances were
studied in vitro in eight of the dialysers at a single "blood"
flow rate of 200 mI/mm and dialysis fluid flow rate of
500 mI/mm, at minimum transmembrane pressure to
produce these conditions. The chosen substances (Table 5)
were labelled with radio-isotopes and were measured in a
scintillation counter with a statistical counting error below
I %. The method is described in greater detail elsewhere [7].
Residual blood volume was measured after an 800 ml
saline wash-in. The fluid remaining in the dialyser and lines
was recirculated through a one liter bottle of 0.04%
ammonia solution for ten mm. The residual blood volume
was calculated from the formula:
U (100 + volume of dialyser and lines in ml)RBV = 200 S
where U is the hemoglobin concentration of the recirculated
fluid and S is the hemoglobin concentration of a sample of
arterial blood taken at the end of dialysis and diluted 1:200
with 0.04% ammonia.
This method of measuring residual blood volume was
criticised by Will and colleagues [8] who claimed that hemo-
globin was not easily estimated at the levels in the final
dilution. We have not found this a limitation of the method;
after a five ml test injection of blood, estimated RBV is
consistently between 4.5 and 5.5 ml. However, this method
may fail to detect blood which is clotted within the dialyser
[9]. We therefore dismantled our dialysers after measure-
ment of RBV. Only in three varieties did we find colored
clot in more than an occasional dialyser. These were the
Gambro Alwall, Gambro Lundia and Cordis HFAK. We
made no attempt to study the importance of blood clot in
the Gambro-Alwall, since this has been investigated in
detail by Muir, Lindsay and Davison [9].
In the Gambro Lundia there was a thin line of clot near
the exit ports and along the edges of some compartments.
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The volume of blood involved appeared negligible but in
order to check this we studied seven dialysers used by pa-
tients whose red cells had been tagged with 51Cr. The blood
content of the washout fluid was measured by hemoglo-
binometry and 51Cr counting; the mean results were 2.0
and 1.6 ml respectively. The membranes and adherent clot
were then placed in a bulk counter; a further mean volume
of 1.4 ml blood was detected. This has been added to the
washout volume to give the answer shown in Table 6.
In the Cordis HFAK residual blood was largely in the
form of a clot within occluded fibres which was inaccessible
to the washing fluid. Residual blood volume was therefore
measured by counting the 51Cr-labelled red cells in the core
of the dialyser, using a bulk counter, and comparing the
count with that from a five ml sample of blood taken at the
end of dialysis and diluted to the same volume as the core.
The statistical counting error was less than 1 % and the
maximum error due to counting geometry less than 3 %
whatever the position of the clot. The volume of blood
remaining in the lines was measured by the washout tech-
nique and added to that in the core to give the figure shown
in Table 6.
Static and dynamic blood volume and ultrafiltration rate
was measured in vitro at 37° C. Dialysis fluid was used as a
blood simulant to avoid osmotic gradients across the mem-
brane. Dialysis fluid flow rate was set at 500 mI/mm with
minimum negative pressure to produce this flow rate in
parallel flow dialysers; coils were studied under the usual
clinical conditions—a dialysis fluid recirculation rate of
about 2Oliters/min and an occlusive cuff, where appropriate,
inflated to 130mm Hg. Uptake into the dialyser was mea-
sured at two minute intervals from the fall in level in a
graduated reservoir. Transmembrane pressure was in-
creased in steps from the minimum necessary to maintain a
"blood" flow of 200 mi/mm. After each increase in pressure
the uptake was plotted until a consistent straight line graph
due to steady ultrafiltration was obtained. The initial uptake
was then corrected for progressive ultrafiltration during the
equilibration period, to give the increase in dynamic blood
volume. Dynamic blood compartment volume was plotted
against transmembrane pressure and extrapolated back to
zero to give static priming volume. This is a largely theoret-
ical parameter since dialysers do not operate at zero trans-
membrane pressure but the change in volume from 0 to
100 mm Hg transmembrane pressure gives a rough idea of
the initial uptake into the dialyser as blood pump speed is
increased from the slow starting rate to normal working
conditions. The further increase in dynamic volume as
transmembrane pressure is increased from 100 to 200 mm
Hg indicates the additional extracorporeal volume during
rapid ultrafiltration.
The coils studied all have high internal resistance. At a
blood flow rate of 200 mI/mm they have a mean transmem-
crane pressure of 130 to 150 mm Hg when venous pressure
is zero. Their priming volume has been quoted at this
pressure.
All ultrafiltration data in Table 6 are based on at least
three studies for each type of dialyser.
Results and Discussion
The design characteristics of the 17 dialysers studied are
listed in Table 2 and the results are summarised in Tables
3—6 and Figs. I and 2.
Clearance (Tables 3 to 5, Figs. 1 and 2). Mass transfer
characteristics of a dialyser are most easily studied in vitro
using aqueous blood simulants. This permits precise control
of temperature and pressure, accurate measurement of
"blood" flow and modification of blood and dialysis fluid
flow rate and pressure over a wide range. We have carried
out such studies on several of the dialysers listed in Table 2;
the results for two are given in Table 5; the in vitro results
overestimate performance in vivo (Tables 3—4) by a few per
cent. However with a few dialysers the discrepancy is much
wider. For instance the Rhone Poulenc 1 B, a multilayer
parallel flow dialyser had in vitro clearances 20 to 25 %
higher than its performances in vivo [6]. This may be due to
sedimentation of blood cells in the low velocity pathway as
has been demonstrated in another muitilayer dialyser, the
Gambro Aiwail [9] or it may reflect greater inequality of
blood flow through the layers when a more viscous solution
(blood) is employed.
We have therefore carried out most of our studies of urea
and creatinine clearance in vivo. Such studies are subject to
several sources of error not encountered in vitro. Blood flow
rate is more difficult to measure accurately. We have found
the measurement of bubble transit time over a two meter
track more consistent than the alternative methods, electro-
magnetic and ultrasonic flowmeters, but its accuracy at flow
rates above 200 mi/mm falls to about Dextrose and
other chromogens introduce a small error into the measure-
ment of creatinine in vivo, which is discussed in the Methods
section. The diffusion barrier at the red cell wall causes a
reduction in clearance in proportion to the haematocrit
[10]. Outflow pressure from the dialyser cannot be con-
trolled entirely at will since it depends in part on the resist-
ance of the return vein. There is therefore a wider scatter of
results when clearance is studied in vivo than in vitro.
Nonetheless, we have found that it is possible to keep this
scatter acceptably close as shown by the standard errors and
correlation coefficients in Tables 3 and 4. Wide variations
in hematocrit of patients under test have been avoided; all
groups used for the study of one dialyser had a mean hema-
tocrit between 21 % and 26% with one exception (Meltec
Multipoint 0.77 sq. m.; mean hematocrit — 30%). From the
data of Grossman and Kopp [10] it can be calculated that
the clearance of urea at 200 mi/mm is diminished by 1 %
for every rise in hematocrit by 2%. Since this is a small
effect in comparison with our observed differences between
dialysers, and since there are no published data from which
to calculate a correction for creatinine clearance, we have
presented our results uncorrected for hematocrit.
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Table 2. Dialysers evaluated at Newcastle upon Tyne from 1971 to 1972
Dialyser Manufacturer Type of Dialyser Surface
area, m2
Membrane
Meltec Multipoint [231 Meltec Ltd., Bourne End
Buckinghamshire, U.K.
Reusable multipoint Ku! 1.07
0.77
0.61
Cuprophan
Cuprophan
Cuprophan
11 i
11 i
11i
Watson Marlow Ku! [16] Watson Marlow Ltd., Falmouth
Cornwall, U.K.
Reusable Kill 1.02 Cuprophan 1111
Watson Marlow Ku! [5, 17]
and Bier Inserta
Staynes Laboratories, Bishop
Auckland, Co. Durham, U.K.
Disposable membrane insert
for Kiil dialysers
1.02 Cuprophan 11 t
Dasco SP 400 Dasco S.P.A. Mirandola, Italy Disposable multipoint 2 layer
insert requiring press
0.95 Cuprophan 13.5 t
Rhone Poulenc lB [37]
Rhone Poulenc ID
Rhone Poulenc, Paris, France
Rhone Poulenc, Paris, France
Disposable 8 layer flat plate
requiring press
0.84
0.88
Cuprophan
Cuprophan
12 t
12 t
Gambro AIwall [25, 38] Ab Gambro, Lund, Sweden Disposable 11 layer flat
plate, free standing
1.00 Cuprophan 22 i
Gambro Lundia [39] Ab Gambro, Lund, Sweden Disposable 17 layer flat
plate, free standing
1.00 Cuprophan 18 ji
Cordis Dow [26, 27] Cordis Corporation,
Miami, U.S.A.
Disposable fibre bundle 1.00 Cellulose
fibers
30 ji
Ultraflo 2
Ultraflo 100
Ultraflo 100
Nephravon
Travenol Laboratories,
Illinois, U.S.A.
Travenol Laboratories,
Illinois, U.S.A.
Travenol Laboratories,
Illinois, U.S.A.
Avon Medicals,
Birmingham, U.K.
Disposable coil cartridge
.
Disposable coils requiring
inflatable cuff
1.00
1.00
1.00
1.00
Cuprophan
Cuprophan
Cellulose
Cuprophan
18 t
18 i
30 i
18 t
EXO3 [28, 29] Extracorporeal Medical
Specialities Inc.,
Philadelphia, U.S.A.
Disposable coil cartridge 0.84 Cuprophan 18 t
Meltec Multipoint 1 m2
Meltec Multipoint 0.77 m2
Cordis Dow
Ultraflo 100
Nephravon
Ultraflo 2. EX-03
Meltec Multipoint 0.61 m2
Dasco SP400 Multipoint
Watson Marlow Ku! + Bier Insert
Gambro Lundia
Rhone Poulenc ID
Watson Marlow Kiil
Fig. 1. Comparative in vivo urea clearance for hemodialysers tested at Newcastle upon Tyne from 1971 to 1972.
a the Bier-Staynes Insert has now been withdrawn from the market in Great Britain.
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Fig. 2. Comparative in vivo creatinine clearance for hemodialysers tested at Newcastle upon Tyne from 1971 to 1972.
Table 3. In vivo urea clearance of dialysers tested in Newcastle upon Tynea
Dialyser
No. of
Experimental
Observations
Blood Flow (ml/min)
100 150 200 250
Flat plate
Meltec Multipoint 1 m2 144 (r= O.971)b 91 l.0C 118 1.0 139 1.4 156 2.3
Meltec Multipoint 0.77 m2 54 (r=0.982) 88 1.3 113 1.3 131 2.0 145± 3.0
Meltec Multipoint 0.61 m2 60(r=0.978) 80± 1.0 101 1.0 116± 1.5 127± 2.5
Watson Marlow Kiil and Bier Insert 75(r=0.958) 78± 1.4 93±2.0 106±2.5 116±4.0
Watson Marlow Kiil 106 (r=0.918) 67± 1.5 83 1.2 96 2.0 107± 3.0
F/at plate (disposable)
Dasco Multipoint SP 400 79 (r=0.957) 73± 1.2 94± 1.2 109± 2.0 121 3.2
RhonePoulenc lB 177 (r=0.796) 63± 1.0 74± 1.3 82±2.0 87±2.6
RhonePoulenclD 57(r=0.770) 74±3.5 89±2.0 99±3.0 106±6.0
Gambro AIwall 69 (r= 0.911) 55 1.3 67 1.6 76 3.0 82 4.0
Gambro Lundia 104 (r=0.891) 74± 1.8 91 1.4 104± 2.0 113 3.0
Hollow fiber
Cordis Dow 27(r=0.861) 84±2.3 108±3.0 126±6.0 141±8.0
Coil
Ultraflo2 39(r=0.945) 71±3.0 95±2.3 113±5.0 128±9.0
Ultraflo 100 61 (r=0.939) 76± 1.0 101± 1.0 120± 1.4 136±2.0
Ultraflo 100 Cellophane 59(r=0.923) 72±2.0 91± 1.3 104±2.2 114±3.4
Nephravon 52(r=0.990) 77±1.7 99±0.8 117±1.5 130±2.3
EX-03 67 (r= 0.986) 75 1.0 97 1.0 114 1.4 126 2.0
a Dialysis fluid flow of 500 mI/mm at a temperature of 37° C.
b Correlation coefficient of curve in parenthesis.
C Clearance figures refer to mean 95% confidence limits of the mean.
Ideally, clearance data should be corrected for ultra-
filtration [4]. This is particularly important in the case of
high molecular weight solutes and it is simple in the case of
in vitro studies during which inflow and outflow pressures
and volumes can be accurately monitored. Our in vitro
data in Table 5 are therefore corrected for ultrafiltration.
During in vivo studies of smaller molecules the correction is
less important and harder to calculate. Ultrafiltration rate
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Table 4. Tn vivo creatinine clearance of dialysers tested in Newcastle upon Tynea
No. of Blood flow (mi/mm)
Dialyser Experimental
Observations 100 150 200 250
Flat plate
Meltec Multipoint 1 m2 144 (r=0.924)b 76± 1.4e 98 1.2 113 2.0 125 3.0
Meltec Multipoint 0.77 m2 55 (r 0.964) 74 1.4 91 1.3 103 2.0 112 3.0
Meltec Multipoint 0.61 m2 62 (r= 0.950) 64 1.2 80 1.0 89 1.7 98 2.5
Watson Marlow Kiil and Bier Insert 77(r=0.945) 60± 1.0 73± 1.3 82±2.0 88± 2.4
Watson Marlow Kiil 99(r=0.861) 56± 1.4 65± 1.3 73± 1.8 80± 3.0
Flat plate (disposable)
Dasco Multipoint SP 400 77 (r=0.944) 61 1.2 76 1.0 88 2.0 96 3.0
Rhone Poulenc 1 B 171 (r=0.576) 40 1.0 52 1.6 61 2.5 65 3.0
RhonePoulenclD 59(r=0.780) 58±3.0 70±1.7 79±2.3 85±4.0
Gambro AIwall 71 (r=0.905) 43± 1.0 53± 1.3 59± 2.2 64± 3.0
Gambro Lundia 103 (r=0.813) 61 1.8 76± 1.3 87± 1.8 95± 2.8
Hollow fiber
Cordis Dow 27(r=0.950) 66± 3.0 84± 4.0 97± 6.0 108± 1.0
Coil
Ultraflo 2 39 (r=0.931) 60± 3.0 78 1.8 91 4.0 102± 7.0
Ultraflo 100 61 (r= 0.900) 67 1.0 85 1.0 99 1.3 109 2.0
Ultraflo 100 Cellophane 59 (r=0.855) 59± 2.0 72± 1.3 80± 2.0 87± 3.0
Nephravon 52(r=0.985) 68±1.0 87±1.1 102±2.0 114±3.0
EX-03 66 (r=0.927) 64± 1.5 80± 1.5 92± 2.3 100± 3.5
a Dialysis fluid flow of 500 mI/mm at 37° C.
b Correlation coefficient of curve in parenthesis.
c Clearance figures refer to mean 95% confidence limits of the mean.
Table 5. Comparative in vitro clearances for small and middleweight molecular solutes
Dialyser Membrane Urea Creatinine 51Cr-EDTA '251-Hypaque 58Co-Vitamin B12
thickness (MW = 60) (MW = 113) (MW = 398) (MW= 630) (MW= 1355)
Meltec 1 m2 11 micron 148.8±7.3 125.8±3.1 77.3±4.3 65.3±5.6 32.9±2.8
(N=9)U (N=9) (N= 12) (N=27) (N=25)
Meltec 0.61 m2 11 micron 47.0±0.8 21.3± 2.1
(N= 5) (N= 6)
Watson Marlow Kiil 11 micron 97.0±7.9 83.6± 10.8 44.0±2.4 22.1±3.8
(N=11) (N=12) (N=lO) (N=10)
Meltec 1 m2 18 micron 128.0± 2.8 101.6± 2.5 56.7± 6.8 45.2± 3.0 21.3± 3.3
(N=6) (N=6) (N=7) (N°°=l2) (N=11)
Watson Marlow KiilC 18 micron 84.7 7.8 70.4± 6.1 27.2± 2.9 10.8 1.6
(N= 9) (N= 9) (N= 9) (N= 9)
Gambro Lundia 18 micron 35.6± 3.5 15.6± 2.1
(N=21) (N=18)
Ultraflo 100 18 micron 45.0± 3.3 20.8± 2.5
(N=9) (N=9)
Cordis Dow 30 micron 36.7 3.4 12.5 2.7
(N=12) (N=18)
a Results represent mean standard deviation and are corrected fDr ultrafiltration effects.
b Dialysis fluid flow of 500 ml/min, blood flow of 200 mI/mm and temperature of 38° C.
c Results uncorrected for ultrafiltration effects.
U Number of evaluations on which mean SD based.
cannot be equated with weight loss during dialysis shown by have therefore performed our studies under conditions of
serial bed weighings and the simpler method of correction minimum ultrafiltration and have reported our results un-
described by Kramer et al [11] gives a considerable scatter corrected for ultrafiltration. They therefore underestimate
even with their precaution of quadruplicate analysis. We true clearance by a small amount. The error is highest at
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high blood flow rates and is greater with the high ultra-
filtration coils than with the flat bed dialysers. However,
the underestimate is small — about 1 % for urea and 3 % for
creatinine at a blood flow rate of 300 mI/mm with a high
ultrafiltration coil [11].
We have chosen clearance rather than dialysance as our
criterion of performance since it is the characteristic of
greatest interest to the clinician. The flat bed and hollow
fiber kidneys are used in single pass so their clearance is
identical to their dialysance. The coils on the other hand
perform poorly in single pass [121 and are usually employed
in an RSP system with a high recirculation rate. In such a
system clearance varies throughout the course of dialysis.
At the start when there is no metabolite in the recirculation
volume, it equals dialysance. It then falls as metabolite
accumulates until an equilibrium state is achieved; in the
conditions of our experiments this occurs towards the end
of the first half-hour. Thereafter the changes are too small
to be of much clinical significance. We have therefore used
the measured clearance in the second to fourth hour as the
best basis for comparison with single pass dialysers. This
parameter underestimates the performance of coils since it
takes no account of the higher clearance in the first half
hour. The underestimate varies with the size of the patient,
recirculation volume, coil performance, blood and dialysis
flow rates and duration of dialysis. In the conditions of our
experiments it is less than 1 % so we have not introduced
any correction for it.
Many dialyser comparisons have been made on the basis
of dialysance which gives a spurious advantage to coils used
in RSP systems. This is a much larger distortion of the
results than any of the methodological errors so far dis-
cussed. For instance the EX-03 coil with a dialysance of
151 mI/mm at a blood flow rate of 200 ml/min appears at
first sight to have a superior performance to the flat plate
Meltec Multipoint 1 m2 (dialysance 139 mI/mm) and the
hollow fiber Cordis HFAK (126 ml/min). However, under
normal running conditions, using the same dialysis fluid
addition rate of 500 mi/mm, the Meltec and Cordis have
clearances equal to their dialysance, but the EX-03 in an
RSP system has a clearance of only 114 mI/mm and is there-
fore inferior to its two rivals.
Since many previous evaluations have been in terms of
dialysance a formula for calculating clearance from dialy-
sance in an RSP system would be useful. Such a formula
has been derived in Appendix 1 and is:
dialysance
—
1+ dialysis fluid addition rate
Using urea and creatinine clearance as our criteria of
performance we rate the I m2 Meltec Muitipoint well ahead
of any of its rivals and even the 0.77 m2 version of this
dialyser is superior to any other we have tested. We have
not examined the pyramid dialysers sold by American manu-
facturers, which are of similar construction to the Meltec
multipoint, but the published data of others [13, 14] suggest
that their performance is not dissimilar.
Of the disposable dialysers the Cordis HFAK has the best
performance in well de-aerated dialysis fluid but suffers
more than other dialysers from the accumulation of air if
de-aeration is incomplete, particularly at the high negative
pressures required for adequate ultrafiltration [15]. There
is little to choose between the Ultraflo 100, Ultraflo 2,
Nephravon and EX-03 coils. They are followed closely by
the Dasco SP 400, Gambro Lundia and Rhone Poulenc 1 D
each of which has clearances 20 to 40% better than its
predecessor (Dasco SP 200, Gambro AIwall and Rhone
Poulenc 1 B). The Kiil dialyser, even in a high performance
version like the Watson Marlow [16], is now low in the
league for performance but can be improved to the level of
the new flat bed dialysers by the use of disposable envelopes
of the Bier [17] or Nose [181 types.
Clearance of "middle molecules" (Table 5). The pro-
position that substances several times heavier than urea and
creatinine are responsible for many of the manifestations
of renal failure has been championed by Scribner and his
colleagues [19, 20] and is gaining support from other
groups [14, 21, 221. The evidence is inconclusive and must
remain so until the hypothetical toxins are identified but the
existence of the theory has led the Gotch Committee to
recommend that for new dialysers "some index of higher
molecular weight permeability must be available to correlate
clinical response to dialysers with increased permeability to
specified larger molecules" [4]. In Table 5 we present data
on six of the dialysers studied in vitro at a single "blood"
and dialysis fluid flow rate in the usual clinical range. At
these flow rates the clearance of large molecular weight
substances is at or close to its maximum with all current
dialysers using cuprophan membrane. Our results confirm
the theoretical prediction that dialysers with thick membrane
will have selective reduction of "middle molecule" clear-
ance. They show that the superiority of the Meltec multi-
point over the Ku! and its newer rivals is maintained over
the "middle molecular" range. Similar results were ob-
tained by Edson, Keen and Gotch [14] with an American
multipoint dialyser. The 0.61 m2 version of the Meltec
Multipoint is virtually identical to the 1 m2 Kiil in clear-
ance over the whole molecular range from urea to vita-
min B12.
Static and dynamic blood compartment volumes (Table 6).
Low static and dynamic blood compartment volumes are
indicative of slight membrane distortion with increasing
transmembrane pressure and a thin blood film thickness,
both of which are essential in a high performance dialyser.
They also indicate a small and stable volume of blood out-
side the body. We suggest that the parallel flow dialysers
should be compared at a trans-membrane pressure of 100
mm Hg since all of them operate at about that pressure
when run at a blood flow of 200 mI/mm, with minimum
dialysis fluid negative pressure for a flow rate of 500 mI/mm.
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Table 6. Comparative characteristics of dialysers tested at Newcastle upon Tyne from 1971 to 1972
a Blood flow of 200 mI/mm. Dialysate flow of 500 mI/mm.
C Hemoglobin estimation technique.
The increase in dynamic volume with a further 100 mm
Hg applied pressure is small (less than 25 ml) with all of
these dialysers.
Coils in general have larger priming volumes than parallel
flow dialysers. However, the largest contributor to extra-
corporeal volume in Britain is the excessively long arterial
venous lines which have been adopted as standard through-
out the country. These contribute more volume than any of
the dialysers and in our view they should be re-designed.
Dialysers with low static and dynamic compartment
volumes suitable for use with small children include the
0.61 m2 Meltec Multipoint [23], the Cordis HFAK and the
Rhone Poulenc the volume of which can be varied by using
only some of the eight parallel compartments. Smaller
dialysers suitable for babies have been described by Busel-
meier, Shideman and Kjellstrand [24].
Flow resistance. We studied the resistance of the blood
flow compartment of all the dialysers quoted here in vitro
and the results are available from the authors on request.
The coils have too high a resistance for operation by blood
pressure alone. All of the parallel flow dialysers can be
operated in this manner but our experience with a restricted
group of patients possessing A-V shunts is not favourable.
d 51Cr technique. e Measured in vivo.
Mean of arterial and venous pressure taken
as transmembrane pressure in coils.
Most of the flow rates obtained were in the region of 80 to
120 ml/min which is well below the optimum performance,
and in the multi-layer dialysers these flow rates were asso-
ciated with an increased incidence of clotting in the dialyser
in spite of heparinisation which is adequate for pumped
hemodialysis. Since the A-V fistula is gradually taking over
as the normal method of access to the circulation, at least in
Britain, we have not included flow resistance as one of our
essential parameters for comparison of dialysers.
Ultrafiltration (Table 6). Ultrafiltration measured in vitro
is not identical to that in vivo but it nevertheless provides
a valuable guide; the effect of plasma protein and osmotic
pressure is small compared with that of pressures generated
in the dialyser. A large number of variables during clinical
dialysis including losses and gains from excretion and in-
gestion, osmotic and thermo-osmotic forces obscure the
effect of ultrafiltration in vivo, and result in very variable
losses of body weight under given conditions of dialysis
[25]. We have, therefore, used in vitro measurements in
ultrafiltration to compare dialysers.
The ultrafiltration requirements of a dialyser depend on
the frequency and duration of dialysis and the fluid intake
between dialysis. Our patients, like most of those in Britain,
Membrane Blood compartment volume, Mean residual In vitro ultrafiltration, Initial Dialysis
thickness ml, at transmembrane pressurea blood volume mi/mm, at mean capital cost, £
after 800 ml transmembrane pressure dialyser dialysis
saline wash-in
micron mm Hg ml mm Hg £
100 2000 100 200
Flat plate
Meltec Multipoint 1 m2 11 72 125 143 (N=16) 2.8 (N=29) 5.9 11.8 (N=16) 345 1.60
MeltecMultipointo.77m2 11 85 110 120 (N=16) 1 (N=10) 4.4 8.6 (N=16) 325 1.60
Meltec Multipointo.61m2 11 72 102 112 (N=16) 1 (N=6) 2.8 5.6 (N=16) 325 1.60
Watson Marlow and
Bier Insert 11 92 140 178 (N26) 5 (N=9) 3.6 7.3 (N3l) 3.60
Watson Marlow Kiil 11 102 140 162 (N14) 2 (N9) 3.6 7.3 (N20) 300 1.60
Disposable flat plate
Dasco SP 400 13.5 82 135 154 (N=23) 2 (N=l2) 3.8 7.6 (N22) 9.50
RhonePoulenc lB 12 156 180 205 (N=15) 5 (N14) 2.5 5.0 (N18) 10.60
Rhone Poulenc 1 D 12 137 178 191 (N= 12) 4.5 (N= 6) 2.8 5.6 (N— 16) 10.60
Gambro AIwall 22 11.0 (N=20) — 7e (N=4) 12.00
Gambro Lundia 18 107 145 167 (N=15) 30 (N=36)
47d (N= 10)
3.6 7.3 (N=l4) 11.00
Hollow fiber
Cordis Dow 30 80 84 88 (N=15) 350 (N=7)
lld (N=7) 2.3 4.5 (N=15) 9.50
Coil
Ultraflo lOO 18 — 305 — (N=6) 1.2 (N=ll) 3.0k 6 (N=13) 7.10
Ultraflo lOOt 30 — 285 — (N=6) 2.4 (N=6) 2.7 5.3 (N=13) 7.10
Ultraflo 2 18 — 265 — (N=13) 9.5 (N=8) 4.4 11.6 (N=l8) 7.10
EX03b 18 — 186 — (N=2l) 1.6 (N14) 5.5 11 (N=22) 7.50
Nephravonb 18 — 280 — (N=6) 5.5 (N=6) 4.5 9 (N14) 6.50
b Evaluated in an RSP system. Dialysis fluid recirculation rate of 20 liters/mm.
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are on thrice-weekly ten hour hemodialysis. For this purpose
one requires a dialyser with a low ultrafiltration rate under
normal running conditions, but an easily adjustable increase
on demand. These requirements are met by the Kiil for
which fluid removal can be adjusted from 2 to 3 mi/mm
to 6 to 7 mI/mm, using a proportioning system which gen-
erates a maximum negative dialyser pressure of 250 mm
Hg. Most of the other parallel flow dialysers described here
have a similar satisfactory range of ultrafiltration rate.
The one exception is the Multipoint 1 m2 which has a
rather high basal ultrafiltration rate making it unsuitable
for patients who tolerate ultrafiltration poorly. The Cupro-
phan coils also have a high obligatory loss of 5 to 6 mi/mm
under normal running conditions due to their high internal
resistance.
The Cordis HFAK is the only dialyser described here for
which the ultrafiltration rate is too low. It is only 4.5 mI/mm
at a transmembrane pressure of 200 mmHg. If it is ne-
cessary to remove more than two liters in a ten hr dialysis,
a specially adapted proportioning system is required with
negative pressure up to 500 mm Hg. This increases the
requirements for adequate de-aeration of the dialysis fluid.
Residual blood volume (RB V) (Table 6). We used a
standard 800 ml saline wash-back to permit comparison
between dialysers and because we dislike the use of air and
air-saline wash-in techniques with their attendant risk of air
embolism. This volume is commonly required by patients
on thrice weekly ten hour dialysis in order to compensate for
losses by ultrafiltration, and wash-in volumes of this size
are usual in Britain where a no-transfusion policy is rig-
orously applied. They may be considered unusually large in
other countries where shorter dialysis times are employed or
where minimisation of blood losses is given lower priority.
All the dialysers tested had acceptably low RBV ex-
cept the Gambro Aiwall and the Cordis HFAK. The
higher RBV of the Gambro Aiwall [9, 261 has been discussed
in the Methods section. This disadvantage has been eli-
minated in its successor, the Gambro Lundia.
Clotting within the fibres was responsible for the rather
high RBV of 11 ml of the Cordis HFAK. Gotch et al [27]
found an RBV of 12 ml for dialysers completing at least two
dialyses but if those completing less than two dialyses are
included the figure rises to 20 ml, a blood loss of 260 ml!
month.
Easterling, Schultz and Knepley [28] found an RBV of
17 ml following first use which fell to less than seven ml per
dialysis thereafter. Certain individual patients seem parti-
cularly prone to clotting within the Cordis HFAK. In a
small group of patients studied with the 51Cr technique, we
could not find any correlation between pre-dialysis clotting
tests and residual blood volume, so these susceptible
patients can only be found by trial and error.
Convenience. The handling characteristics of the Multi-
point dialysers are very similar to those of the Kiil. All of
the disposable parallel flow dialysers and the Cordis HFAK
have proved easy to handle in our experience. The Gambro
Lundia is a particularly attractive dialyser from this point
of view since it can be plugged straight into the equipment
used for Kiil dialysis without any modifications. The Cordis
HFAK is equally easy to handle but requires modification
of the negative pressure system, a more complicated arterial
line and an additional monitor. The Dasco SP 400 and the
Rhone Poulenc 1 B and 1 D require special clamping frames.
Once these are provided they are easy to assemble. Coils are
also convenient when used with the equipment designed for
them, but the need to pressure test the coils in view of the
current high leak rate with all the varieties tested increased
the assembly time by about 15 mm.
Two important aspects of convenience are the leakage
rate and pyrogenicity but these cannot be readily assessed in
trials on small numbers of dialysers as described here. In
our experience the blood-to-dialysis-fluid leak with the Kiil
has averaged 3 % [26] but it varies with the dialyser, the
batch of membrane and especially the technician; one ob-
sessional technician has had only two blood leaks in 2000
dialyses. Observations on several hundred dialyses are there-
fore required to demonstrate that any new dialyser has a
lower leakage rate than the Kiil. However it requires only a
short experience to confirm that the leak rate from all
Cuprophan coils is high [29, 30].
Pyrogen reactions are rare with all disposable dialysers.
We have not encountered outbreaks with any of the new
non-disposable dialysers described but since reactions occur
episodically with the Kiil and the overall rate is well below
1 % we will need several years of observation with the new
designs before comparative data are meaningful.
Cost. Cost is an important factor in the comparison of
dialysers. Relative costs vary in different countries but the
British prices (without arterial and venous lines) shown in
Table 6 give a rough idea of the price differentials. The
price per dialysis for the non-disposable dialysers (Kiii and
Multipoint) includes the capital cost written off over two
years. We have not included the capital cost of special clamps
for use with disposable parallel flow dialysers as these can
usually be obtained on free loan from the manifacturers if
the disposables are ordered in quantity. Even so the use
of a non-disposable dialyser saves about £8 (US $20) per
dialysis compared with a typical disposable dialyser used
once only. This more than offsets the labor costs in Britain
and we suspect that it does so in most other countries. The
price differential diminishes if a disposable dialyser is reused
but its advantage in convenience is then also diminished.
Choice of dialyser. The purpose of this article is to provide
data which will assist the clinician in making his own choice
of dialyser, taking into account his local circumstances such
as the availability of finance, skilled staff, space and reliable
delivery. However our own opinion based on experience of
all the dialysers described may be of some interest.
Our choice is restricted by the fact that we have, for the
last eight years, relied mainly on the Kiil dialyser and our
capital equipment is designed for use with the Kill. This
must be a common situation since the Kiil dialyser has
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been the choice of the majority of European units during
the 1960's [2]. We have chosen the Meltec 1 m2 Multipoint
as our standard equipment for regular hemodialysis. Its
considerable advantages over the Kiil have led us to start
re-equipment of our 100 patients without waiting for the
Kiils to wear out. However, we propose to keep some Kiils
in service by adopting the Bier-Staynes envelopes; these
will be kept for patients who cannot tolerate the higher
ultrafiltration of the multipoint dialyser.
The use of non-disposable dialysers probably carries some
risk of disseminating hepatitis during reassembly. However,
so far there is no evidence that hepatitis is more prevalent
in centers using locally assembled dialysers than in those
using disposable equipment [31, 32] suggesting that this
factor is less important than transfusion policy screening
for Australia antigen and isolation of infectious patients
[33—35].
Nonetheless sharing of non-disposable dialysers between
patients is undesirable and is proscribed in the Rosenheim
Committee report [36]. There is, therefore, a need for a
disposable dialyser which can be easily substituted for the
Kiil/Multipoint during hospital admission, holiday visits or
interruption of dialysis by blood leaks. For these purposes
we have chosen the Gambro Lundia since it requires no
additional equipment.
The exclusive use of disposable dialysers has obvious
attractions and is justifiable when finance is a less important
limitation than space or technical staff. The Cordis HFAK
has the best clearance of small molecules but the worst
residual blood volume. The Ultraflo and other Cuprophan
coils are not far behind in clearance and have very low
RBV but their rather high rupture rate may be equally im-
portant as a cause of blood loss. Experience with disposable
flat plate dialysers is too short to permit firm statements
about their rupture rates but so far they appear to be low
and this will compensate for their lower clearance. We do
not think there is a clearly defined "best buy" among the
disposable dialysers; our choice when we can afford to
make it will be heavily influenced by data which has still to
be collected on rupture rate.
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D — Qb(A-V) 2A—BB (
C A—B
D= A
D (A —B)
A
After the first few minutes of dialysis, inflow of metabolite
into the recirculating volume =outflow, i. e.
CA = QdB
B—-- (4)Qd
Dialyser
Dialysance
rn//rn/n
Measured
clearance
mi/mm
Calculated
clearance
mi/mm
EXO3 (Cuprophan) 151 114 116
Nephravon (Cuprophan) 154 117 118
Ultraflo 100 (Cellophan) 132 104 104
Appendix
A simple formula for converting coil dialysance to clear-
ance for comparison with flat plate dialysers can be derived
for an RSP system with a very small recirculating volume as
follows:
D =coil dialysance C =coil clearance
A arterial concentration V =venous concentration
B =concentration in re-
circulating volume
Qb ==blood flow Qd =dialysis fluid
addition rate
By definition:
C — Qb(A-V)
A ()
and
Dividing (1) and (2)
(3)
Substituting for B in (3)
/ CADIA—----
C— \ Qi —D CD D'l Qd— A Qd C
D
1+D/Q
This formula assumes an infinitely small recirculating vol-
ume but even with a finite volume up to four liters measured
and calculated clearance are in good agreement (Table 7).
Table 7. Comparison of measured and calculated clearance of
coils in Lucas RSP coil attachment a,b
a Blood flow 200 mI/mm, dialysis fluid addition rate 500 ml/min.
b Temperature 37° C, recirculation rate 20 liters/mm, recircula-
tion volume 2—4 liters.
